PO.TB10.01 · 肿瘤生物学

p53缺失细胞在胃食管肿瘤起始中充当超级竞争者

p53-null cells act as supercompetitors in gastroesophageal tumor initiation

海报缩略图:p53缺失细胞在胃食管肿瘤起始中充当超级竞争者
编号 2271 展板 20 时间 4/20 09:00–12:00 区域 Section 33 主讲 Kyle LaBella
分会场 Tumorigenesis and Early Microenvironmental Trajectories
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Kyle LaBella, Efren Reyes, Mathijs Verhagen, Priyanka Kulkarni, Shadi Tarazi, Shawn Gillespie, Oana Ursu, Louis Vermeulen

Genentech, Inc., South San Francisco, CA

摘要 Abstract

中文摘要
TP53是癌症中最常见的突变基因,常在恶性转化前数十年即可在组织学正常的组织中被检出。p53缺失细胞相较于邻近的野生型细胞具有竞争优势,然而在健康组织内抑制其生长扩增、或在疾病中驱动其扩增的机制仍知之甚少。在此,我们利用长期活细胞克隆示踪结合单细胞RNA测序,在一种新型Barrett食管模型中研究了p53失活的作用。利用胃干细胞与食管鳞状上皮的类上皮共培养系统,我们发现胃上皮p53缺失相较于邻近的野生型食管鳞状细胞赋予了强大的竞争优势,通过主动抑制相邻野生型细胞增殖而导致突变克隆扩增。从机制上讲,这些p53缺失细胞表现出高水平的染色体不稳定性,从而驱动一种改变的分泌组,抑制野生型基底细胞的生长。引人注目的是,p53缺失细胞对这些抑制因子保持抗性。此外,通过在p53野生型邻近细胞中敲除细胞周期检查点通路,或通过阻断p53缺失细胞中赋予其对分泌型抑制因子抗性的通路,均可恢复中性竞争。总的来说,这些发现揭示了p53失活如何改变胃食管交界处竞争性干细胞动态,并为Barrett食管个体的癌症阻断提示了潜在策略。
查看英文原文 English abstract
TP53 is the most frequently mutated gene in cancer and is often detected in histologically normal tissues decades before malignant transformation. p53-null cells possess a competitive advantage over neighboring wildtype cells, yet the mechanisms that restrain their outgrowth within healthy tissue or drive their expansion in disease remain poorly understood. Here, we investigated the role of p53 inactivation in a new model of Barrett's esophagus using long-term live-cell clonal tracing coupled with single-cell RNA sequencing. Using an epithelioid co-culture system of gastric stem cells and esophageal squamous epithelium, we found that gastric epithelial p53-loss confers a strong competitive advantage over neighboring wildtype esophageal squamous cells, leading to the expansion of mutant clones via the active suppression of adjacent wildtype cell proliferation. Mechanistically, these p53-null cells exhibit high levels of chromosomal instability, which drives an altered secretome that represses the growth of wildtype basal cells. Strikingly, p53-null cells remain resistant to these inhibitory factors. Additionally, neutral competition was restored either by deleting cell cycle checkpoint pathways in p53-wildtype neighbors or by blocking the pathways in p53-null cells that confer resistance to secreted inhibitory factors. Collectively, these findings reveal how p53 inactivation alters competitive stem cell dynamics at the gastroesophageal junction and suggest potential strategies for cancer interception in individuals with Barrett's Esophagus.
利益披露 Disclosure
K. LaBella, None.. E. Reyes, None.. M. Verhagen, None.. P. Kulkarni, None.. S. Tarazi, None.. S. Gillespie, None.. O. Ursu, None.. L. Vermeulen, None.

← 返回 AACR 2026 检索